Xgeva and Hyperparathyroidism secondary - a phase IV clinical study of FDA data

Summary:

Hyperparathyroidism secondary is reported as a side effect among people who take Xgeva (denosumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Coreg, and have Prostate cancer metastatic.

The phase IV clinical study analyzes which people have Hyperparathyroidism secondary when taking Xgeva. It is created by eHealthMe based on reports of 37,636 people who have side effects when taking Xgeva from the FDA, and is updated regularly.

What is Xgeva?

Xgeva has active ingredients of denosumab. It is often used in breast cancer. eHealthMe is studying from 37,717 Xgeva users. Check the latest studies of Xgeva.

What is Hyperparathyroidism secondary?

Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary) is found to be associated with 697 drugs and 462 conditions by eHealthMe. Check the latest studies of Hyperparathyroidism secondary.

On Jul, 17, 2026

37,636 people reported to have side effects when taking Xgeva.
Among them, 12 people (0.03%) have Hyperparathyroidism secondary.

Could Xgeva cause Hyperparathyroidism secondary?

Among these 12 people:

How long have people been on Xgeva when they have Hyperparathyroidism secondary? *

What is the gender of people who have Hyperparathyroidism secondary when taking Xgeva? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Hyperparathyroidism secondary when taking Xgeva? *

What are other drugs people take besides Xgeva? *

What are other side effects people have besides Hyperparathyroidism secondary? *

Hypocalcaemia (levels of calcium in blood serum are abnormally low): 11 people, 91.67%
Hypophosphataemia (electrolyte disturbance in which there is an abnormally low level of phosphate in the blood): 6 people, 50.00%
Diarrhea: 5 people, 41.67%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 4 people, 33.33%
Nausea (feeling of having an urge to vomit): 4 people, 33.33%
Oedema Peripheral (superficial swelling): 3 people, 25.00%
Hypokalemia (low potassium): 3 people, 25.00%
Metabolic Acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body): 3 people, 25.00%
Nausea And Vomiting: 3 people, 25.00%
Weakness: 2 people, 16.67%

What are the existing conditions these people have? *

Prostate Cancer Metastatic: 3 people, 25.00%
Renal Cell Carcinoma (a kidney cancer): 2 people, 16.67%
Fibrous Dysplasia Of Bone (an abnormal bone growth where normal bone is replaced with fibrous bone tissue): 2 people, 16.67%
Swelling: 1 person, 8.33%
Pain: 1 person, 8.33%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 1 person, 8.33%
High Blood Pressure: 1 person, 8.33%
High Blood Cholesterol: 1 person, 8.33%
Hiccups (an involuntary spasm of the diaphragm and respiratory organs, with a sudden closure of the glottis and a sound like a cough): 1 person, 8.33%
Constipation: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Xgeva and have Hyperparathyroidism secondary?

- Check whether Hyperparathyroidism secondary is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xgeva:

Xgeva (37,717 reports)

Browse all side effects of Xgeva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperparathyroidism secondary:

Hyperparathyroidism secondary (697 drugs)

Browse all the conditions that are associated with Hyperparathyroidism secondary:

Hyperparathyroidism secondary (462 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on denosumab (the active ingredients of Xgeva) and Xgeva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.